Shionogi and Ferrer concluded an exclusive promotion agreement for RIZMOIC® (naldemedine) in Spain for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative.
Shionogi’s research and development efforts target pain/central nervous system as one of its priority therapeutic areas of interest.
Ferrer’s activity covers the entire health spectrum in Spain and many other countries worldwide, including expertise in pain management by opioid treatment. The company’s commitment to improving the wellbeing of society and its integrated model spanning from R&D through to distribution, ensures their range of products offer real benefits in rapidly changing environments.
“We are delighted to collaborate with Ferrer in Spain. This collaboration marks an additional key milestone for the launch of RIZMOIC® in Europe,” Dr. John Keller, Chief Executive Officer of Shionogi B.V., the subsidiary of Shionogi in Europe, said. “Ferrer is a company that is well trusted and highly respected, with not only an established commercial structure that is ideal for the introduction of RIZMOIC®, but also a deep knowledge of pain management that augments and aligns with our own.”
“We are pleased to partner with Shionogi on this promising treatment which has the potential to make a real impact on the lives of many people currently suffering from OIC across Spain,” Ferrer’s Chief Executive Officer, Mario Rovirosa, said. “This partnership allows us to introduce an innovative treatment to reduce the burden in this disease area. Moreover, this agreement complements our expertise in the field of pain relief”.
On February 18, 2019, the European Commission (EC) granted the Marketing Authorization (MA) for RIZMOIC® for the treatment of OIC in adult patients who have previously been treated with a laxative. RIZMOIC® is planned to be launched in Spain in 2020. RIZMOIC® was launched under the brand name Symproic® in Japan in June 2017, and in the United States in October 2017.